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Thyroid hormone has significant impact on skin homeostasis and 
cutaneous wound healing. Previous research has demonstrated both in vitro 
proliferation of keratinocytes and fibroblasts and in vivo stimulation of epidermal 
and dermal layers in response to triiodothyronine (T3) administration. However, 
the physiological mechanism of action involving T3 signaling and the specific 
intermediate factors of T3-induced cell proliferation are poorly understood. 
Currently, there is no working model of T3-dependent dermal fibroblast 
proliferation. In order to gain a more complete understanding of thyroid hormone 
regulation in wound healing, two known proliferative growth factors, connective 
tissue growth factor (CTGF) and proliferative cell nuclear antigen (PCNA), were 
chosen as potential mediators of T3-stimulated fibroblast proliferation. In vitro 
dermal fibroblast cultures were dosed with one of three experimental T3 
concentrations (10-9 M, 10-8 M and 10-7 M) and western blot analysis was 
 iv 
conducted to determine whether CTGF and PCNA expression are regulated by 
T3 stimulation. The results indicated no significant change in CTGF or PCNA 
expression dependent on T3 concentration. The implications of the findings were 
addressed and suggestions for future research directions have been proposed. It 
is still unclear which growth factors are involved in T3-regulated fibroblast 
proliferation. Once these mediators are identified, it will be possible to construct a 
mechanism of action to integrate the findings and ultimately develop a complete 
understanding of cutaneous physiology.    
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Thyroid Hormone Overview 
Thyroid hormones (TH) are multipurpose systemic regulators of fetal and 
juvenile development and play a major role in adult metabolic homeostasis. Most 
tissues and organs respond to TH and consequently its cumulative effects may 
be measured by systemic oxygen consumption and metabolic rate (Werner & 
Ingbar’s the Thyroid, 2005; Yen, 2001). The diversity of cell types modulated by 
TH activity implicates its importance. Some of the major systems affected by TH 
include the heart, muscle, liver, bone, brain, and skin (Yen, 2001). The variety of 
anabolic and catabolic properties of TH action further illustrate its importance in 
metabolic regulation and homeostasis. Table 1 provides an overview of the 
complexity of systemic TH action.    
The thyroid gland, located in the anterior neck, produces TH, derived from 
the amino acid tyrosine. Biosynthesis of TH occurs exclusively in the thyroid 
gland and requires dietary iodine. Large amounts of iodine can be stored within 
the gland, allowing for the accumulation of a three-month reserve (Brent, 2012; 
Yen, 2001). Thyroglobulin (TG) is synthesized within in the follicular cells of the 
thyroid gland and contains tyrosine ring residues within its amino acid sequence. 
TG is secreted into an extracellular storage compartment, the colloid space, 
where iodination of tyrosine occurs followed by tyrosine ring coupling, TH 
formation and subsequent TH storage (Figure 1).  
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Table 1. Overview of thyroid hormone systemic effects. 
 
Figure taken from Thyroid Physiology presentation by Dr. Seaton, 2012. Boston 
University School of Medicine. 
 
The major secretory product of the thyroid gland is tetraiodothyronine 
(thyroxine or T4), at a rate of 80-100 µgm/day. T4 is primarily a prohormone that 
may be converted into the biologically active triiodothyronine (T3) or its inactive 
isoform reverse triiodothyronine (rT3) by a family of selenium deiodinase 
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enzymes. Type 1 deiodinase (D1) and type 2 deiodinase (D2) convert T4 into T3 
and may also degrade T3 during periods of elevated TH in serum (Bianco & Kim, 
2006; Bianco et al., 2002). D1 is activate in liver and kidney while D2 functions in 
the pituitary, brain and adipose tissue (Huang et al., 2011; Yen, 2001). Type 3 
deiodinase (D3) is primarily active in skin and is responsible for the conversion of 
T4 into rT3, a major regulatory step in TH activity (Huang et al., 2011; Yen, 2001). 
Peeters et al., (2013) have recently demonstrated that D3 is critical for normal 
functioning of the hypothalamus-pituitary-thyroid axis. In D3 knockout (KO) mice, 
follicular cells in the thyroid become unresponsive to thyroid stimulating hormone 
(TSH) and consequently the mice develop hypothyroidism. As such, D3 may be 
the most important deiodinase regulating TH homeostasis (Barca-Mayo et al., 
2011; Peeters et al., 2013). 
 
Figure 1. Thyroid hormone biosynthesis. Figure taken from Thyroid Physiology 
presentation by Dr. Seaton, 2012. Boston University School of Medicine.  
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T4 demonstrates a higher degree of molecular stability, as evidenced by 
its 7-day half-life compared to the 1-day half-life of T3. As such, T4 is utilized as a 
TH reservoir in plasma (Brent, 2012; Werner & Ingbar’s the Thyroid, 2005; Yen, 
2001). The majority of circulating T4 and T3 are bound to the plasma proteins 
thyroxine binding globulin (TBG), albumin and transthyretin to prevent TH 
destruction, while a miniscule amount of unbound TH determines biological 
activity. Extrathyroidal deiodinase activity in the liver accounts for 80% of 
circulating T3 derived from the T4 precursor. Although T4 is 40 times more 
abundant in plasma than T3, 90% of thyroid hormone nuclear receptors (TR) in 
target cells bind preferentially to T3 to execute biological activity (Werner & 
Ingbar’s the Thyroid, 2005).   
Circulating plasma TH levels are tightly controlled by negative feedback 
inhibition involving the hypothalamic-pituitary-thyroid axis (HPTA). Thyrotropin-
releasing hormone (TRH) is synthesized and secreted by the median eminence 
and arcuate nucleus within the hypothalamus. TRH travels through the 
hypophyseal portal system to the anterior pituitary, where it binds to TRH 
receptors along the cell membrane of thyrotrope cells, which subsequently 
triggers exocytosis of secretory granules containing thyroid stimulating hormone 
(TSH). TSH enters systemic circulation and binds to TSH receptors along the 
follicular cells of the thyroid gland, inducing the release of T4 and T3 (Oetting & 
Yen, 2007). The classic negative feedback loop model applies to the HPTA, 
where end products, T4 and T3, inhibit production of earlier hormones in the axis, 
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TRH and TSH. TH exerts inhibitory effects on both the hypothalamus and 
pituitary by binding to nuclear receptors within these tissues and suppressing the 
expression of TRH and TSH, respectively (Figure 2) (Brent, 2012; Werner & 
Ingbar’s the Thyroid, 2005). Several additional hormones also regulate the 
HPTA. Glucocorticoids inhibit TRH synthesis, decrease TRH receptor affinity to 
TRH and inhibit deiodinase conversion of T4 into T3 thus decreasing TH 
biological activity. Dopamine and somatostatin inhibit thyrotropes from 
synthesizing and secreting TSH (Werner & Ingbar’s the Thyroid, 2005).  
 
Figure 2. Hypothalamic pituitary thyroid axis. Negative feedback regulation from 
end products T4/T3 to earlier products TRH and TSH. Figure taken from Brent, 
2012.  
 
Thyroid hormones primarily function through a genomic mechanism of 
action within target cells. THs enter cells through high-affinity plasma membrane 
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carriers, a regulatory step in TH activity (Yen, 2001). Intracellular D2 converts T4 
into T3 and any excess T3 is subsequently inactivated into rT3 by D3. In the 
nucleus, T3 binds with thyroid hormone nuclear receptors (TR), which belong to 
the retinoid/thyroid/vitamin D superfamily of nuclear receptors (Oetting & Yen, 
2007; Yen, 2001). Three TR isoforms (TR-α1, -α2 and -β) have been identified. 
TRs possess multiple binding domains for the regulation of TH activity. One TR 
domain is bound to a DNA sequence uniquely related to TH gene expression, 
known as a thyroid hormone response element (TRE). In the absence of T3, TR 
is bound to a corepressor protein that inhibits modification of the TRE. However, 
when T3 is present, TRs heterodimerize, bind with a coactivator, a retinoid X 
receptor (RXR) and together with the TRE, mediate TH regulated genes (Figure 
3) (Brent, 2012). The number of TRs within a cell determines the degree of 
biological activity in response to T3 stimulation. Several tissues, including the 
liver and heart, contain large quantities of TRs and thus express large changes in 
protein expression when stimulated by T3.  
There is also recent evidence that TH displays non-genomic effects in 
some target cells. In these cells, there is a rapid onset of action in response to 
TH stimulation that involves signaling cascades, independent of TRs and gene 
expression (Yen, 2001). T3 has been implicated in Ca2+-ATPase, Na+/K+-ATPase 
and Na+/H+-ATPase activation in addition to mitogen-activated protein kinase 
(MAPK) and phosphoinositide 3-kinase (PI3K/Akt) pathways (Aranda et al., 2009; 
Kress, Samarut, & Plateroti, 2009; Lin et al., 2012). T3   also  enhances  glucose  




Figure 3. Thyroid hormone action on target cell. T3 enters the nucleus and binds 
to the TR-coactivator-RXR-TRE complex to activate DNA translation and protein 
expression. Figure taken from Brent, 2012.  
 
 
absorption into cells via adenyl cyclase activation, suggesting it can mediate 
other cell membrane transporters (Aguayo-Mazzucato et al., 2013). There is 
further evidence that T3 mediates mitochondrial activity (Chocron et al., 2012; 
Kvetny et al., 2009; Sterling & Brenner, 1995; Sterling, 1991), affects 
cytoskeleton polymerization (Farwell, DiBenedetto, & Leonard, 1993; Zamoner et 
al., 2007) and potentiates the effects of cytokines in host defenses (Huang et al., 
2012; Ilias et al., 2007; Lin, Thacore & Davis, 1994). This culminating research 
provides an alternative view of the role of TH and suggests TH can act both 
genomically and non-genomically in target tissues. Further research is necessary 
to understand the full impact of TH biological activity. However, insights from 
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thyroid-related pathology have served as a template for identifying TH target 
tissues and discovering the underlying TH-dependent physiology.  
As noted earlier, TH is necessary for normal human development. 
Children in TH-deficient states present with perturbations in bone maturation and 
brain development, regardless of normal growth hormone (GH) levels. Thyroid 
dysfunction is more common in females, likely as a consequence of higher rates 
of autoimmune disease in women. In addition to autoimmunity, several other 
factors cause thyroidopathy including iodine deficiency, radiation exposure, 
pituitary dysfunction and thyroid cancer (Gessl, Lemmens-Gruber, & Kautzky-
Willer, 2012).   
Hyperthyroidism, also known as thyrotoxicosis, is the result of elevated 
serum TH. The primary cause of thyrotoxicosis is Graves’ Disease, an 
autoimmune disorder which produces TSH receptor-stimulating antibodies that 
mimic TSH, bind with TSH receptors on the thyroid gland and cause TH 
hypersecretion (Eckstein et al., 2009; Werner & Ingbar’s the Thyroid, 2005). The 
classical symptom of Graves’ Disease is exophthalmos, the accumulation of 
mucopolysaccharides in the orbital cavity leading to protrusive eyes. 
Systemically, elevated serum TH leads to overstimulation of beta-adrenergic 
receptors and promotes tachycardia, hyperdefecation, increased basal metabolic 
rate and generalized anxiety (Gessl et al., 2012; Safer, 2011).  
Hypothyroidism is characterized by reduced levels of serum TH caused by 
insufficient TSH stimulation resulting from pituitary dysfunction or by diminished 
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TH secretion of the thyroid gland. Hashimoto’s Thyroiditis is a leading cause of 
hypothyroidism in the United States, whereby autoantibodies target follicular cell 
proteins, disrupting normal functioning of the thyroid gland (Lee & Hasteh, 2009; 
Werner & Ingbar’s the Thyroid, 2005). Initially patients present with enlarged 
thyroids, clinically defined as goiters, that result from inflammatory responses in 
autoimmunity. In late-stage thyroiditis, the thyroid gland atrophies. Diminished 
serum TH causes bradycardia, lethargy, reduced metabolic rate, cold intolerance 
and memory impairment (Safer, 2011). Extreme fluxes in TH levels can cause 
life-threatening emergencies including thyroid storm (hyperthyroidism) or 
myxedema coma (hypothyroidism) (Gessl et al., 2012).   
Of particular interest are the skin manifestations resulting from 
thyroidopathy. Hyperthyroid dermopathy includes hyperhydrosis, 
hyperpigmentation and erythma, all resultant from an increased basal metabolic 
rate. Skin appears smooth and thin, often associated with alopecia (Safer, 2011). 
Hypothyroid cutaneous symptoms are characterized by pale skin, xerosis and 
myxedema, the accumulation of glycosaminoglycans leading to edematous 
states (Safer, 2011). Clinical observations of TH-dependent skin are often 
complicated by the fact that most thyroidopathy is autoimmune in nature and 
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The Integument System  
The skin serves as a protective barrier, shielding the host from the 
external environment. It is an essential nonspecific defense against infection and 
plays a vital role in maintaining fluid volume and electrolyte balance (McLafferty, 
Hendry, & Alistair, 2012). Skin is comprised of three distinct layers. The 
epidermis is the outermost layer, composed of sheet-like configurations of 
keratinocytes undergoing continuous differentiation beginning from basal stem 
cells along the basement membrane. The epidermis protects against UV 
radiation, fluid loss and contains pro-inflammatory cytokines for rapid pathogenic 
defense. Beneath the basement membrane exists the dermis, composed 
primarily of resident fibroblasts, extracellular matrix (ECM) and a rich 
vasculature. The dermis is crucial to maintaining homeostasis and is largely 
responsible for wound repair following tissue damage. The innermost layer is the 
hypodermis containing adipocytes for thermoregulation and fat reserves for 
energy utilization (McLafferty et al., 2012).    
Following tissue injury, three phases of wound healing reconstruct the 
damaged region and attempt to restore integument to its original state: 
inflammation, proliferation and tissue remodeling (Baum & Arpey, 2005; Werner 
& Grose, 2003). The process does not occur in discrete stages, but instead 
works as a coordinated mechanism involving several cell types, cytokines, 
growth factors, structural proteins and enzymes. The immediate response to 
tissue damage is vasoconstriction and clot formation via fibrin and platelet 
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aggregation. This action minimizes excessive hemorrhagic loss, creates a barrier 
against invading pathogens and releases cytokines involved in the reparation 
process (Werner & Grose, 2003).  
Subsequent inflammatory responses begin within hours of tissue damage 
and include hyperemia, via histamine and leukotrienees C4 and D4, and 
increased permeability of local capillaries, via complement C3a and C5a, to 
facilitate diapedesis of neutrophils (Demidova-Rice, Hamblin, & Herman, 2012). 
Neutrophils are the first cell type to invade the wound site, largely in the form of 
polymorphonuclear cells (PMNs), and are responsible for apoptosis and 
phagocytosis of damaged cells and surrounding debris. Complement C3a and 
C5a, thrombin and transforming growth factor beta (TGF-β) also act as 
chemokines to recruit monocytes and lymphocytes to the wound site. Once 
monocytes enter interstitial space they transform into macrophages and continue 
the degradation of necrotic tissue. Macrophages also release fibroblast growth 
factor 2 (FGF-2), TGF-β and connective tissue growth factor (CTGF) that induce 
myofibroblast differentiation, migration and stimulate resident fibroblasts in the 
dermis to synthesize structural components of the ECM. Vascular endothelial 
growth factor (VEGF) and angiopoietin stimulate neoangiogenesis, which serves 
to oxygenate and nourish the migrating and proliferating cells (Table 2) (Baum & 
Arpey, 2005; Demidova-Rice et al., 2012).  
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Table 2. Wound healing: cells, growth factors and time intervals. 
 
The procession of wound healing involves coordinated action from many cell 




The recruitment of fibroblasts, macrophages and leukocytes, the 
deposition of ECM and the induction of angiogenesis defines granulation tissue 
and commences the transition into the proliferative phase of wound healing 
(Baum & Arpey, 2005). The proliferative phase begins 24 hours after tissue injury 
and may persist for days to weeks depending on wound severity. Re-
epitheliazation of keratinocytes, involving migration, proliferation and cell 
differentiation, is also characteristic of the proliferative phase. Tissue remodeling 
involves wound contraction via myofibroblast activity to reduce the surface area 
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of the site of injury and diminish scar tissue deposition. The remodeling phase 
also replaces ECM type III collagen with type I collagen for enhanced tissue 
durability (Figure 4) (Werner & Grose, 2003).   
 
Figure 4. Stages of cutaneous wound repair. A: Inflammation. Blot clot formation 
and neutrophil invasion. B: Proliferation. Macrophage phagocytosis, epithelial 
migration, angiogensis and cell proliferation. C: Tissue Remodeling. 
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Myofibroblast contraction and collagen deposition. Figure taken from Werner & 
Grosse, 2003.  
 
Of particular interest is the role of CTGF in the proliferative phase of 
wound healing. CTGF is released by platelets, macrophages and fibroblasts 
(Blalock et al., 2012; Grotendorst & Duncan, 2005; Igarashi et al., 1993). It 
belongs to the CNN family of proteins, which share 38 homologous cysteine 
residues and four structural binding domains (Baum & Arpey, 2005; Seher et al., 
2011; Werner & Grose, 2003). The numerous binding domains enable CTGF to 
interact with numerous cytokines, membrane receptors and proteoglycans, 
contributing to a large display of biological activity. CTGF is regarded as a 
multifunctional matrixcellular protein (Leask & Abraham, 2003). TGF-β induces 
CTGF mRNA synthesis in dermal fibroblasts uniquely during wound healing 
(Chujo et al., 2005; Igarashi et al., 1993; Mori et al., 1999) via the Protein Kinase 
C (PKC) and ras/MEK/ERK pathway (Chen et al., 2004; Leask & Abraham, 
2003). CTGF promotes fibroblast proliferation, myofibroblast differentiation, 
induces ECM remodeling and functions as a downstream regulator of TGF-β by 
increasing the affinity of TGF-β type II receptors to their ligand. The most 
prominent function of CTGF is the promotion of fibroblast cell adhesion during 
the proliferative phase of wound healing by binding directly to heparin sulfate 
proteoglycans (HSPG) and stimulating the interaction between integrins and 
fibronectin (Figure 5) (Chen et al., 2004; Leask & Abraham, 2003). Furthermore, 
CTGF overexpression is constitutively found in dermal fibrotic scar tissue and is 
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believed to play a critical role in fibrotic disease (Igarashi et al., 1993; Seher et 
al., 2011; Werner & Grose, 2003). 
  
 
Figure 5. Proposed mechanism of connective tissue growth factor (CTGF) cell 
binding. Figure taken from Leask & Abraham, 2003.   
 
Another key element of interest in the proliferative phase of wound healing 
is the role of proliferating cell nuclear antigen (PCNA) in fibroblasts. PCNA is a 
homotrimeric ring-shaped protein found in all eukaryotic cells and is a marker of 
proliferation (Scovassi & Prosperi, 2006). It is synthesized in S and early G1 
phases of the cell cycle and is essential for DNA replication and repair, active in 
DNA polymerase processivity and an important contributor of cell cycle control 
(Chiara et al., 2012; Hergott & Kalnins, 1991; Scovassi & Prosperi, 2006). It is 
also a critical regulator of cell proliferation and apoptosis during acute 
inflammation (Chiara et al., 2012) and is induced by oxidative DNA damage and 
cell destruction (Savio et al., 1998). Post-translational ubiquitination of PCNA can 
occur via three different mechanisms and regulators, all modifying the same 
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lysine residue (Hoege et al., 2002), which suggests PCNA serves alternative 
functions dependent on the needs of the cell. During the proliferative phase of 
wound healing, PCNA is involved in DNA replication and cell division of dermal 
fibroblasts and keratinocytes (Onuma, Mastui, & Morohashi, 2001).          
 
Thyroid Hormone Action in Wound Repair 
TH acts directly on skin through TRs found throughout the epidermis and 
dermis. All TR isoforms (TR-α1, -α2 and -β) have been identified in skin cells 
(Ahsan et al., 1998), including keratinocytes, fibroblasts, vascular endothelial 
cells, smooth muscle cells and multiple cell types devoted to hair follicles. D3 (T4 
into rT3) and D2 (T4 into T3) activity has been reported in skin (Safer et al., 2003; 
Schröder-van der Elst et al., 1998), with D3 the most prominent deiodinase (Villar 
et al., 2000). Deiodinase activity is critical to TH regulation and the homeostasis 
and physiology of skin. Contreras-Jurado et al., (2011) have recently 
demonstrated that TRs, in addition to TH, are important regulators of the 
inflammatory response during wound healing. In comparison to wild-type (WT) 
mice, TR knockout (KO) mice displayed augmented inflammatory responses 
after administration of 12-O-tetradecanolyphorbol-13-acetate (TPA), a pro-
inflammatory agent, demonstrating that TR is necessary for skin homeostasis. 
The authors discovered the TR KO mice had increased p65/NF-kB and STAT3 
pathway activation causing overexpression of pro-inflammatory cytokines and 
chemokines. TR KO mice also demonstrated reduced keratinocyte proliferation, 
   
 
 17 
attributed to decreased expression of cyclin D1 (Contreras-Jurado et al., 2011). 
This recent evidence concludes that both TH and TR are necessary for normal 
skin metabolism and homeostasis.  
  In vitro studies have also provided support that TH stimulates keratinocyte 
and fibroblast proliferation. Safer et al., (2004) have shown that T3 stimulates 
expression of keratin genes, promoting wound healing. Keratins 1 (K1) and 10 
(K10) trigger epidermal differentiation, while K6a, K16 and K17 are responsible 
for epidermal proliferation and production of intermediate filaments. Keratin gene 
KO mice demonstrated diminished epidermal thickness and delayed wound 
repair (Safer, Crawford, & Holick, 2004; Wojcik, Bundman, & Roop, 2000). TH 
also inhibits production of collagen, fibronectin and hyaluronic acid in fibroblasts, 
suggesting it is involved in controlling fibrosis during wound healing (De Rycker, 
Vandalem, & Hennen, 1984; Murata et al., 1987; Smith et al., 1982). 
Interestingly, when keratinocytes and fibroblasts were cocultured, T3 produced 
divergent effects in contrast to cells cultured separately. When cultured in 
isolation, keratinocyte and fibroblast proliferation both followed a T3 dose-
dependent trend, with maximal effect at 0.5 nM T3 for keratinocytes and 0.1 nM 
T3 for fibroblasts (Safer et al., 2003). However, when keratinociytes were 
cocultured with fibroblasts, T3 administration inhibited keratinocyte proliferation 
(Safer et al., 2003). The greatest inhibition of keratinocytes occurred when 
fibroblasts were maximally stimulated at 0.1 nM of T3. The authors suggested 
that T3 promoted inhibitory signals (not yet identified) in fibroblasts to block 
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keratinocyte proliferation.  
In order to understand the effect of TH on cocultured cells, consideration 
of in vivo studies is necessary.  Topical application of exogenous T3 in mice has 
been shown to stimulate epidermal proliferation, dermal thickening, hair growth 
(Safer et al., 2001) and to accelerate wound healing (Safer, Crawford, & Holick, 
2005). Untreated hypothyroid mice have delayed wound healing in comparison to 
hypothyroid mice treated with intraperitoneal (IP) T3. After IP T3 administration 
was discontinued, healing rates reverted to original values (Figure 6) (Safer et 
al., 2004). Another interesting finding concerns the divergent effects of topically 
and systemically (IP) administered T3 in mice. Safer et al., (2003) discovered 
that topical application of T3 produced a dose-dependent rise in epidermal and 
dermal thickness and proliferation, while IP T3 administration caused the 
converse effect of epidermal thinning. Furthermore, topical T3 application had no 
direct effect on serum T3 levels whereas IP T3 administration caused significant 
fluxes in systemic TH homeostasis, including cutaneous metabolism. The results 
suggest that TH possesses both anabolic and catabolic properties in cutaneous 
target tissue and the authors surmise that skin deiodinases may exert a 
neutralizing effect in the event of local or systemic thyrotoxicosis.    




Figure 6. Thyroid hormone dependent wound healing. A: In hypothyroid mice 
wound healing lagged significantly behind healing in mice treated with IP T3. B: 
Hypothyroid mouse with baseline wounds. C: Hypothyroid mouse on day 4. D: IP 
T3-treated mouse at baseline. E: IP T3-treated mouse on day 4. Figure taken 
from Safer et al., (2004).   




As demonstrated in previous research, T3 administration to in vivo mice 
models and in vitro cell cultures significantly increases the rate of cutaneous 
wound healing. However, the physiological mechanism of action involving T3 
signaling and the specific intermediate factors of T3-induced cell proliferation are 
poorly understood. Currently, there is no working model of T3-dependent dermal 
fibroblast proliferation.    
The goal of the present study is to investigate potential growth factors 
involved in dermal fibroblast proliferation in response to T3 stimulation. 
Specifically,  
(1) Determine whether connective tissue growth factor (CTGF) expression is 
regulated by T3 concentration.  
(2) Determine whether proliferating cell nuclear antigen (PCNA) expression is 
regulated by T3 concentration.  
(3) Propose a theoretical mechanism of action for thyroid hormone-dependent 
fibroblast proliferation involving CTGF and PCNA. 
The study will conduct western blot analyses of in vitro dermal fibroblast 
cultures after administration of selected T3 concentrations. The ultimate goal is a 
better understanding of T3 function in wound repair that can be exploited for 
clinical application in patient populations who present with impaired wound 
healing capability.   
 





Cell Culturing  
Human dermal fibroblasts were cultured from primary skin samples 
donated from discarded tissue following neonatal circumcision at Boston Medical 
Center. Growth media was produced using Dulbecco’s-modified Eagle’s medium 
(DMEM) (Cat#12430-054, Gibco Life Technologies), 5% fetal bovine serum 
(FBS) (Cat# SH30088.03, HyClone ThermoScientific) and 1% amphotericin B 
antibiotic (Cat# 17-745E, Lonza). Fibroblasts were isolated from the tissue 
samples, nourished with growth media and incubated at 37°C in 5% CO2 until 
80% confluence was achieved.       
 
Cell Passing 
Growth media was removed from the fibroblast stock plate, then 3 mL of 
ethylenediaminetetraacetic acid (EDTA) solution was added, swirled for 10 
seconds and removed. EDTA solution was made from 100 mg EDTA stock 
powder (Cat# AM9260G, Invitrogen) and 500 mL phosphate buffered saline 
(PBS). 3 mL of trypsin (Cat# T4549-100ML, Sigma-Aldrich Co.) was added to the 
stock plate and incubated for 10 minutes. Next, 3 mL of media (DMEM, FBS, 
antibiotic) was added to the stock plate to neutralize trypsin. The fibroblast 
solution was dislodged from the stock plate using a 10 mL pipet then added to a 
14 mL tube and centrifuged for 5 minutes. The supernatant was removed from 
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the centrifuge tube and the fibroblast pellet was resuspended with 1 mL of media 
per experimental plate. Each experimental plate had 9 mL of media and 1 mL of 
resuspended fibroblast solution added. Plates where incubated for 3-5 days. 
Media was replaced every 3 days until 80% confluence was achieved.      
 
Dosing 
Media was removed from each experimental plate and washed with 3 mL 
of PBS, repeated twice. Next, 10 mL of DMEM was added to each plate. T3 stock 
solutions where prepared by combining 6.5 mg of T3 powder (Cat# 06B262013, 
ICN Pharmaceuticals), 40 µL of 5 M NaOH and 10 mL of distilled H2O. T3 
dilutions were prepared as follows: 10 µL of 10-3 M T3 stock solution was added 
to a plate containing only 10 mL DMEM, forming a 10-6 M T3 solution. To produce 
the 10-7 M T3 experimental plate, 1000 µL of the 10-6 M T3 solution was added to 
the first experimental plate. To produce the 10-8 M T3 experimental plate, 100 µL 
of the 10-6 M T3 solution was added to the second experimental plate. To 
produce the 10-9 M T3 experimental plate, 10 µL of the 10-6 M T3 solution was 
added to the third experimental plate. A fourth experimental plate was left as a 
control, without addition of T3. Each experimental plate then received 100 µL of 
double-stripped bovine serum (DSS). DSS was made from 500 mL of FBS, 25 g 
of resin (Cat# 142-2822, Bio-Rad Laboratories) and 15 g of activated charcoal 
(Cat# 242276, Sigma-Aldrich Co.). Plates were incubated overnight (12-18 
hours).    




Experimental plates were washed with 3 mL of EDTA. EDTA was then 
removed and 3 mL of trypsin was added. The plates were incubated for 10 
minutes.  To neutrazlie the trypsin, 3 mL of media (without antibiotic) was added. 
The experimental plates were scrapped and pipetted to dislodge the fibroblasts. 
With a 10 mL pipet, each plate of fibroblast solution (10-7 M, 10-8 M, 10-9 M and 0 
M) was added to a 15 mL tube and centrifuged for 5 minutes at 1200 revolutions 
per minute (RPM). The supernatant was then removed. Each tube with remaining 
pellet was resuspended with 250 µL of lysis buffer solution and placed on ice for 
20 minutes. The lysis buffer solution was made by combining one tablet of 
Protease Inhibitor Cocktail (Cat# 11836153001, Roche Diagnostics) to 10 mL of 
RIPA buffer (Cat# R0278-500ML, Sigma-Aldrich Co.) and shaking the lysis buffer 
solution for 10 minutes. Each tube containing the resuspended pellet and lysis 
buffer solution was centrifuged for 10 minutes at 14000 RPM at 4°C. The 
supernatant from each tube was transferred into a 1.5 mL labeled Eppendorf 




50 mL of SDS running buffer stock solution (20X) (Cat# NP0002, 
Invitrogen) was added to 950 mL of distilled H2O to form 1X running buffer 
solution. Transfer buffer stock solution (10X) was made by combining 30.3 g of 
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tris amino methane (Tris Base) (Cat# 69L-9053, Fisher Scientific), 144 g of 
glycine (Cat# 521M-12294, Fisher Scientific) and filling distilled H2O to 1 L and 
shaking to dissolve the solution. Functional transfer buffer (1X) was made from 
100 mL of 10X transfer buffer stock, 200 mL of methanol (Cat# 1700L6808, 




Eppendorf tubes containing experimental T3 solutions (10-7 M, 10-8 M, 10-9 
M and 0 M) were defrosted at ambient temperature for 10 minutes. 13 µL from 
each experimental solution was added to a newly labeled eppendorf containing 5 
µL of lithium dodecyl sulfate (LDS) (Cat# NP0007, Invitrogen) and 2 µL of 
dithiothreitol (DDT)/sample reducing agent (Cat# NP0009, Invitrogen). Samples 
were then placed in a 70°C water bath for 10 minutes.  
The Bio-Rad Mini-Gel Box Electrotransfer kit was assembled according to 
the Bio-Rad instructional protocol, using NuPAGE Bis-Tris gels (Cat# NP0322, 
Invitrogen). Approximately 950 mL of 1X running buffer solution was poured into 
the electrotransfer gel box, overflowing into all chambers. 500 µL of NuPAGE 
antioxidant (Cat# NP0005, Invitrogen) was added to the middle chamber of the 
box. The first well of the gel was loaded with 15 µL of standard ladder (Cat# 
LC5925, Invitrogen) and the remaining wells were loaded with 15 µL of the 
samples. Gel electrophoresis was run at 176 Volts for 35-40 minutes.  




Following gel electrophoresis, the gel was transferred to a nitrocellulose 
membrane (Cat# LC2001, Novex Life Technologies) using the transferring 
cassette apparatus, according to the Bio-Rad instructional protocol. 
Approximately 950 mL of 1X transfer buffer was poured into the transfer box and 
the transfer was run at 220 mA for 50 minutes.  
 
Membrane Blocking and Antibody Incubation 
Following membrane transfer, the nitrocellulose membrane was placed in 
a blotting box with 2 mL of 5% bovine serum albumin (BSA) blocking solution. 
The blocking solution was made from 5 mL of BSA powder (Cat# SH40098.03, 
HyClone ThermoScientific) and 100 mL of Tris-Buffered Saline and Tween 20 
(TBST). The membrane was blocked at ambient temperature for 60 minutes then 
the blocking solution was removed. The primary antibodies of interest, anti-PCNA 
(Cat# sc-7907, Santa Cruz Biotechnology) and anti-CTGF (Cat# H0001490-M01, 
ABNOVA) along with the control antibody β-Actin (Cat# 8H10D10, Cell Signaling 
Technology) were combined into a 1:1000 dilution solution of 6 mL BSA and 6 µL 
of primary antibodies and added to the blotting box. The primary antibody 
solution was incubated overnight at 4°C.  Next, the primary antibody solution was 
removed from the blotting box and the nitrocellulose membrane was washed with 
1X TBST and placed on the vortex machine for 5 minutes, repeated twice. The 
secondary antibody solution containing anti-rabbit at a 1:1000 dilution (6 mL BSA 
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and 6 µL anti-rabbit) and anti-mouse at a 1:5000 dilution (6 mL BSA and 1.2 µL 
anti-mouse) was added to the blotting box and placed on the vortex machine at 
ambient temperature for 60 minutes. The secondary antibody solution was then 
removed and the membrane was washed with 1X TBST and placed on the vortex 
machine for 5 minutes, repeated twice.  
 
Membrane Exposure 
2 mL of enhanced chemiluminescence (ECL) substrate A and 2 mL of 
ECL substrate B (Cat# WP20005, Invitrogen) were added to the blotting box 
containing the nitrocellulose membrane for 5 minutes. In a dark room the 
membrane was placed into a developing cassette and exposed to 
chemiluminescence photographic film (Cat# 28906835, GE Healthcare) for 2-
minute and 8-minute intervals.  





Human dermal fibroblasts were experimentally dosed in vitro with one of 
four T3 concentrations (10-7 M, 10-8 M, 10-9 M and 0 M) and subjected to western 
blot analysis. Two growth factor proteins, CTGF and PCNA, were qualitatively 
analyzed for T3-dependent expression. Both CTGF and PCNA gene expression 
was detected.  
 
CTGF expression in fibroblasts was unchanged by T3  
CTGF expression was measured with respect to the control protein β-
actin. CTGF gene expression was detected in all experimental T3 conditions (0 
M, 10-9 M, 10-8 M, 10-7 M) in equal amounts (Figure 7). There was no evidence 
of change in CTGF expression resulting from T3 concentration (Figure 8). There 
was no measureable difference in nitrocellulose membranes exposed to 
photographic development at 2-minute or 8-minute intervals.  
 
Figure 7. Western blot of connective tissue growth factor (CTGF) from human 
dermal fibroblasts. Top bands represent CTGF, lower bands represent β-actin. 
Lane 1 through 4 represents increasing T3 concentration (0 M, 10-9 M, 10-8 M, 10-
7 M). Measurement scale in kilo Daltons (KDa).  





Figure 8. Percent change in connective tissue growth factor (CTGF) expression 
with T3 concentration. Increasing T3 concentration in fibroblast cultures had no 
effect on overall CTGF expression. Each experimental T3 condition (0 M, 10-9 M, 
10-8 M, 10-7 M) expressed the same amount of CTGF.  
 
 
PCNA expression in fibroblasts was unchanged by T3 
PCNA expression was measured with respect to the control protein β-
actin. PCNA gene expression was detected in all experimental T3 conditions (0 
M, 10-9 M, 10-8 M, 10-7 M) in equal amounts (Figure 9). There was no evidence 
of change in PCNA expression resulting from T3 concentration (Figure 10). 
There was no measureable difference in nitrocellulose membranes exposed to 
photographic development at 2-minute or 8-minute intervals.  




Figure 9. Western blot of proliferative cell nuclear antigen (PCNA) from human 
dermal fibroblasts. Top bands represent β-actin, lower bands represent PCNA. 
Lane 1 through 4 represents increasing T3 concentration (0 M, 10-9 M, 10-8 M, 10-
7 M). Measurement scale in kilo Daltons (KDa).  
 
 
Figure 10. Percent change in PCNA expression with T3 concentration. Increasing 
T3 concentration in fibroblast cultures had no effect on overall PCNA expression. 
Each experimental T3 condition (0 M, 10-9 M, 10-8 M, 10-7 M) expressed the same 
amount of PCNA. 





Thyroid hormones (TH) are active in most tissues and organ systems. 
Thyroid hormone nuclear receptors (TR) are found in numerous cell types 
including hepatocytes, osteocytes, myocytes and neurons. Consequently the 
effect of TH may be measured by systemic oxygen consumption and metabolic 
rate.  TH is essential for normal growth, development and homeostasis in 
humans. Therefore a complete understanding of the role that TH plays in human 
physiology will help elucidate the underlying pathology of many thyroid-related 
disorders.  
The physiological mechanism of action involving TH and cutaneous 
wound healing is still poorly understood. Mounting evidence suggests that TH 
and TRs play an integral role in skin homeostasis, inflammatory responses to cell 
damage and the proliferative and migratory events in the reparatory process 
(Ahsan et al., 1998; Contreras-Jurado et al., 2011; Safer et al., 2003, 2005). The 
current study attempted to identify potential growth factors involved in the 
mediation and propagation of dermal fibroblast proliferation. Once the key 
regulatory components in TH-dependent wound healing are identified, a 
theoretical mechanism of action may be proposed that will integrate the findings 
and establish groundwork for future research. The current study evaluated 
connective tissue growth factor (CTGF) and proliferative cell nuclear antigen 
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(PCNA) as possible growth factors involved in TH-dependent fibroblast 
proliferation.  
CTGF is a multifunctional matrixcellular protein (Leask & Abraham, 2003) 
and a downstream regulator of TGF-β. Previous research demonstrates that 
CTGF stimulates fibroblast proliferation and cell adhesion, ECM remodeling and 
is a major regulator of fibrotic scar tissue (Igarashi et al., 1993; Seher et al., 
2011; Werner & Grose, 2003). Consequently, CTGF was an appealing candidate 
for TH-dependent fibroblast proliferation. Similarly, PCNA is a fundamental 
indicator of cell proliferation (Scovassi & Prosperi, 2006). It is present in all 
eukaryotic cells and has been shown to regulate DNA synthesis and repair 
following cell damage. As such, PCNA is also a logical growth factor to study in 
TH-dependent cutaneous wound healing and fibroblast proliferation.  
Western blot analysis was performed as a preliminary means of identifying 
the proteins upregulated by dermal fibroblasts following in vitro addition of T3 to 
four experimental plates with varying concentrations of T3. Western blotting was 
conducted using CTGF and PCNA antibodies. The results demonstrate that both 
CTGF and PCNA gene expression were present in fibroblast cultures. However, 
neither CTGF nor PCNA expression was altered by TH activation. While there is 
evidence that CTGF and PCNA are present during fibroblast proliferation, it is not 
likely that there is direct regulation via T3 mechanisms.    
CTGF expression was measured in four experimental conditions. 
Fibroblasts were dosed with 10-7 M, 10-8 M, 10-9 M and 0 M of T3. CTGF was 
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qualitatively measured in comparison to β-actin, which served as the control 
parameter. While CTGF expression was observed in each T3 condition (Figure 
7), there was no apparent change in intensity. Each condition displayed the same 
amount of CTGF protein relative to β-actin. CTGF expression was also observed 
in the control condition that lacked T3, suggesting that CTGF does not require T3 
stimulation during fibroblast proliferation.  One potential explanation may clarify 
these results.  It is possible that TH concentrations were insufficient to 
demonstrate any effect on CTGF production. Previous research (Safer et al., 
2003) has demonstrated that T3 stimulates fibroblast proliferation with maximal 
effect at 0.5 nM of T3. The current study used T3 concentrations above, below 
and inclusive of that range without significant effect. Perhaps if the T3 
concentration were augmented to 10-6 M an observable change in CTGF 
expression would occur. Since CTGF is largely expressed in fibrotic diseases, it 
is likely that a greater concentration of T3 would be necessary to induce fibroblast 
production of CTGF and therefore increasing T3 to 10-6 M would be warranted.  
PCNA expression was measured in four experimental conditions. 
Fibroblasts were dosed with 10-7 M, 10-8 M, 10-9 M and 0 M of T3. PCNA was 
qualitatively measured in comparison to β-actin, which served as the control 
parameter. While PCNA expression was observed in each T3 condition (Figure 
9), there was no apparent change in intensity. Each condition displayed the same 
amount of PCNA protein relative to β-actin. PCNA expression was also observed 
in the control condition that lacked T3, suggesting that PCNA does not require T3 
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stimulation during fibroblast proliferation. One possible explanation may delineate 
these results. Since PCNA is indicative of cell proliferation (Scovassi & Prosperi, 
2006) it is possible that the fibroblasts cultured to 80% confluence were overly 
stable and had already achieved maturity. In other words, the majority of 
fibroblasts were not in a proliferative state.  This would support the observation 
that PCNA expression was unchanged regardless of T3 concentration. Future 
research involving T3-dependent PCNA expression should consider using in vitro 
fibroblasts at 50-70% confluence to determine whether any measureable change 
would occur.  
CTGF and PCNA were studied with the intention of proposing a 
mechanism of action for TH-dependent fibroblast proliferation. Since the results 
have demonstrated no qualitative difference in CTGF or PCNA expression, it was 
not possible to hypothesis about a possible intracellular biological mechanism. It 
is still unclear whether T3 induces fibroblast proliferative growth factors via 
genomic or non-genomic signals. Traditionally, T3 binds to thyroid hormone 
nuclear receptors (TR) within target cell nuclei and promote thyroid hormone 
response elements (TRE) to induce DNA expression. However, recent evidence 
suggests that T3 also stimulates non-genomic cellular responses, including 
activation of cell membrane receptors and cytoplasmic signaling cascades 
(Aranda et al., 2009; Kress et al., 2009; Lin et al., 2012). It is therefore possible 
that T3 exerts influence on cutaneous wound healing by either genomic or non-
genomic mechanisms. Furthermore, the possibility that a combination of genomic 
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and non-genomic factors regulate T3-dependent wound healing should also be 
considered.      
The current study was not intended to encapsulate a complete rendering 
of fibroblast activity during the proliferative phase of wound healing, but rather it 
was meant to serve as an introductory sampling of possible growth factors 
involved in the regulatory process. Nonetheless, one key limitation became 
apparent post-facto. The growth media used during fibroblast in vitro cell 
culturing contained fetal bovine serum (FBS) to supplement growth factors 
present in vivo. Previous research has shown that FBS contains endogenous 
levels of T3 (Moeller et al., 2009) and thus could have inadvertently stimulated 
fibroblasts to produce TH-dependent growth factors in the control group (0 M of 
T3). In order to subjugate this possibility, double-stripped serum (DSS) was 
added to the experimental plates during T3 fibroblast dosing to minimize 
extraneous influence of growth factors, cytokines and other lipophilic compounds. 
However, there remains a marginal chance that FBS in the original growth media 
influenced fibroblast growth and subsequent secretory products. Future attempts 
should restrict the use of FBS and use instead a T3-free serum in the growth 
media.  
Furthermore, there are two additional factors that may not contribute 
significantly to the results but should nevertheless be considered. The first 
concerns membrane exposure times during photographic development. The 
current study chose 2-minute and 8-minute exposure intervals with the intent of 
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comparing the results of brief (2-minute) and long (8-minute) exposures. The 
results demonstrated no change in intensity dependent on photographic 
exposure. Although the chosen time intervals for the brief and long conditions 
were presumably disparate, it is worth considering increasing the long exposure 
interval to 12 or 15 minutes in the event that subtle but significant differences 
become apparent.   
The second constraint reflects the qualitative nature of the current 
analysis, which relies heavily on subjective characterizations of intensity 
gradients. For a thorough and objective analysis, future studies should 
incorporate the use of quantifiable software, for instance the use of ImageJ 
Technology, to differentiate among intensity bands in western blot analyses. 
Future directions should also consider the effects of in vitro cocultured 
keratinocytes and fibroblasts with regard to TH-dependent growth factors. 
Previous research by Safer et al., (2003) has demonstrated that T3 inhibits 
keratinocyte proliferation in cocultured fibroblast samples. The authors suggested 
that T3 induced fibroblasts to produce inhibitory proliferative signals directed at 
keratinocytes. However, these proposed inhibitory signals were not investigated. 
By replicating the current study with cocultured samples, it may be possible to 
discover these inhibitory growth factors that act in an autocrine or paracrine 
regulatory mechanism.  
Understanding the role of TH in wound healing is critical to developing 
strategies to treat thyroid-related skin perturbations and aid patient populations 
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who present with impaired wound healing capability. The current study focused 
on identifying the growth factors responsible for TH stimulated fibroblast 
proliferation. At this time, it appears as though CTGF and PCNA may not be 
directly involved in the TH-dependent mechanism of action. Continued research 
should investigate other possible proliferative growth factors with the intent of 
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